

Resource Summary Report

Generated by [NIF](#) on Sep 14, 2026

CD45-PerCP-Vio700, human

RRID:AB_2660425

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-097-527, RRID:AB_2660425

Antibody Information

URL: http://antibodyregistry.org/AB_2660425

Proper Citation: Miltenyi Biotec Cat# 130-097-527, RRID:AB_2660425

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution B cells, basophils, dendritic cells, granulocytes, hematopoietic stem cells, Langerhans cells, leukocytes, lymphocytes, macrophages, mast cells, monocytes, plasma cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-121. (RRID:AB_2725949).

Antibody Name: CD45-PerCP-Vio700, human

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: 5B1

Antibody ID: AB_2660425

Vendor: Miltenyi Biotec

Catalog Number: 130-097-527

Record Creation Time: 20231110T034358+0000

Record Last Update: 20260901T045028+0000

Ratings and Alerts

No rating or validation information has been found for CD45-PerCP-Vio700, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution B cells, basophils, dendritic cells, granulocytes, hematopoietic stem cells, Langerhans cells, leukocytes, lymphocytes, macrophages, mast cells, monocytes, plasma cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-121. (RRID:AB_2725949).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Luoma AM, et al. (2022) Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell, 185(16), 2918.